By now the mechanism has been established: obesity suppresses testosterone through aromatase, inflammation, insulin resistance, and leptin resistance. More fat, less testosterone. This is well documented, consistently replicated, and biologically coherent.
But here is the part that turns a one-directional problem into a trap: low testosterone is itself a driver of fat gain, muscle loss, and worsening metabolic function.
The arrow doesn’t just point one way. It points both ways, simultaneously, and the two effects reinforce each other.
What Testosterone Deficiency Does to Body Composition
Testosterone is an anabolic hormone. In the context of body composition, its roles are specific and consequential:
Muscle mass. Testosterone drives the commitment of pluripotent stem cells toward the myogenic lineage (muscle cells) and inhibits their differentiation into adipocytes (fat cells). In human adipose tissue studied ex vivo, testosterone decreased adipocyte differentiation by approximately 50%. In men receiving androgen deprivation therapy (ADT) for prostate cancer — where testosterone is deliberately suppressed to near-castrate levels — fat mass increases by an average of 3.4 kg and abdominal visceral adipose tissue increases by approximately 22%, with the majority of these changes established within six months of treatment initiation.
This is not a theoretical mechanism. ADT in prostate cancer patients is one of the best natural experiments available for studying what testosterone deficiency does to body composition in men, because the suppression is rapid, severe, and deliberate. The result is unambiguous: remove testosterone, gain fat and lose muscle.
Metabolic rate and insulin sensitivity. Testosterone improves insulin sensitivity through multiple pathways. It reduces expression of lipoprotein lipase in adipose tissue (the enzyme that promotes fat storage), enhances catecholamine-induced lipolysis (fat breakdown), and promotes glucose uptake in muscle. Men with experimentally induced hypogonadism — using GnRH agonist treatment in healthy volunteers — developed measurable increases in fat mass within ten weeks, and insulin resistance deteriorated at a rate consistent with the fat accumulation.
Exercise motivation and capacity. This mechanism is less biochemically elegant but practically important: testosterone affects motivation, physical energy, and exercise capacity. Studies in mice with androgen receptor knockouts showed reduced spontaneous physical activity compared to wild-type mice. In men, a small RCT found that testosterone undecanoate reduced fatigue. Observational data has associated higher endogenous testosterone with maintained physical activity levels in aging men.
A man who is hypogonadal is more likely to feel too fatigued to exercise, less likely to maintain an exercise program, and when he does exercise, less able to build and maintain muscle mass. Each of these effects compounds the tendency toward fat accumulation.
The Self-Perpetuating Cycle
Grossmann, Ng Tang Fui, and Dupuis described this explicitly in their 2014 Asian Journal of Andrology review: “The current evidence suggests a bidirectional relationship between testosterone and obesity in men, initiating a self-perpetuating cycle.”
The cycle can be entered from either end:
A man gains weight → higher adipose aromatase and inflammation → HPT axis suppression → lower testosterone → more fat gain, less muscle, worse insulin sensitivity → more weight → lower testosterone → etc.
A man develops hypogonadism from another cause (medication, illness, age-related change) → lower testosterone → reduced muscle mass and increased fat deposition → more adipose tissue → more aromatase activity → further HPT suppression → lower testosterone → etc.
In the Massachusetts Male Aging Study (MMAS), moving from a non-obese to an obese state over the follow-up period produced a testosterone decline equivalent to approximately 10 years of normal aging. This is a particularly striking comparison: spending time gaining weight is as bad for your testosterone production as spending the equivalent time getting older. And unlike aging, weight gain is in principle reversible.
The longitudinal data from a community cohort of Japanese-American men showed that lower baseline testosterone independently predicted increases in intra-abdominal fat measured at 7.5 years of follow-up — even after adjusting for baseline adiposity. This means that lower testosterone is predictive of future fat gain, independent of how much fat you currently have. The effect is not just a consequence of current obesity; it is a driver of future obesity.
Sarcopenic Obesity: The Worst of Both Worlds
There is a clinical phenotype at the intersection of these two pathologies that has been recognized increasingly in the literature: sarcopenic obesity. This is the combination of excess fat mass and reduced skeletal muscle mass in the same individual.
Sarcopenic obesity is not simply “being overweight and weak.” It is a distinct metabolic phenotype with its own risk profile. The loss of muscle mass associated with hypogonadism (sarcopenia) reduces the metabolic rate, making further weight gain more likely and weight loss less achievable through moderate caloric restriction. The inflammatory cytokines secreted by visceral fat (TNF-α, IL-6) directly impair muscle protein synthesis, driving sarcopenia further. Reduced physical activity from both fatigue and musculoskeletal limitations reduces the caloric expenditure needed to maintain body weight.
Men with prostate cancer receiving ADT develop sarcopenic obesity as a predictable consequence of androgen suppression. In community-dwelling men, lower testosterone — even in the mid-range rather than severely deficient — is associated with higher rates of sarcopenia and functional limitation in longitudinal studies.
The practical consequence of sarcopenic obesity is that standard weight-loss approaches are less effective. A man with sarcopenic obesity who undertakes hypocaloric dieting will lose weight — but a larger proportion of that weight loss will come from muscle rather than fat compared to a metabolically healthy person. This accelerates the sarcopenic component, reduces metabolic rate further, and makes the weight difficult to maintain after loss.
The Combination Approach
Given the bidirectionality, the question of treatment becomes: at which point in the cycle do you intervene?
The evidence supports intervention at both ends. Weight loss unambiguously increases testosterone levels proportional to the amount of weight lost. The 2014 Grossmann review collated 15 published trials: dietary approaches achieved mean weight loss of 6–17% with testosterone increases of approximately 2.9–5.1 nmol/L; surgical interventions achieved 28–44% weight loss with testosterone increases of 7.8–12.5 nmol/L.
But for many men, the cycle is too entrenched for lifestyle intervention alone to generate the weight loss needed to substantially reactivate the HPT axis. The review noted that meaningful free testosterone recovery required weight loss of greater than 15% — a threshold many men cannot achieve with diet and exercise alone, particularly when fatigue and reduced exercise motivation from hypogonadism are themselves limiting factors.
This is the clinical case for a combined approach: address the testosterone deficiency to restore the conditions (energy, muscle mass, exercise capacity, insulin sensitivity) that support successful weight management, while simultaneously addressing the weight to remove the suppressive burden on the HPT axis. Neither intervention, alone, fully addresses the cycle. Together, they attack it from both ends.
The evidence base for this combination approach — TRT plus lifestyle modification — is reviewed directly in the next post.
Next up: Post 5 — “Does TRT Fix Obesity? What the Evidence Actually Shows, What It Doesn’t Show, and Realistic Expectations for Men Starting TRT.”
